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Mutational Analysis in Pediatric Thyroid Cancer and
Correlations with Age, Ethnicity, and Clinical Presentation
Maria Eleni Nikita,1 Wen Jiang,2 Shih-Min Cheng,3 Feras M. Hantash,3 Michael J. McPhaul,3
Robert O. Newbury,4 Susan A. Phillips,1 Richard E. Reitz,3 Frederic M. Waldman,3 and Ron S. Newfield1
Background: Well-differentiated thyroid cancer (WDTC) incidence in pediatrics is rising, most being papillary
thyroid carcinoma (PTC). The objective of the study was to assess the prevalence of different mutations in
pediatric WDTC and correlate the genotype with the clinical phenotype.
Methods: This is a single-center retrospective study. Thyroid tissue blocks from 42 consecutive pediatric WDTC
patients who underwent thyroidectomy between 2001 and 2013 were analyzed at Quest Diagnostics for BRAFV600E,
RAS mutations (N,K,H), and RET/PTC and PAX8/PPARc rearrangements, using validated molecular methods.
Thyroid carcinomas included PTC, follicular thyroid carcinoma (FTC), and follicular variant of PTC (FVPTC).
Results: Thirty-nine samples (29 females) were genotyped. The mean age at diagnosis was 14.7 years (range 7.9–
18.4 years), and most were Hispanic (56.4%) or Caucasian (35.9%). The mean follow-up period was 2.9 years.
Mutations were noted in 21/39 (53.8%), with both BRAFV600E (n= 9), and RET/PTC (n= 6) detected only in PTC.
Mutations were detected in 2/5 FTC (PAX8/PPARc and NRAS) and 3/6 FVPTC cases (PAX8/PPARc). Of 28 PTC
patients, 57.1% had mutations: 32.1% withBRAFV600E, 21.4% withRET/PTC, and 3.6% withNRAS. Of patients with
BRAFV600E, 77.8% were Hispanic and 88.9% were >15 years, while all RET/PTC-positive patients were £15 years
( p= 0.003). Tumor size, lymph node involvement, and distant metastasis at diagnosis (or soon after 131I ablation) did
not vary significantly based on the mutation.
Conclusions: BRAFV600E was the most common mutation, especially in older and Hispanic adolescents. A larger,
ethnically diverse pediatric cohort followed long term will enable the genotypic variability, clinical presentation, and
response to therapy to be better assessed.
Introduction
Thyroid cancer represents the third most commonpediatric solid tumor and the most common endocrine
malignancy (1). The incidence of thyroid cancer in the United
States has been rising in both adults and pediatric patients.
Based on the Surveillance, Epidemiology, and End Results
(SEER) database, the average age-adjusted annual incidence
for thyroid cancer in children 0–20 years old, from 2008 to
2011, was 0.886 per 100,000 persons (2). Pediatric thyroid
carcinoma and especially papillary thyroid carcinoma (PTC)
has a more favorable course compared with adults, with a
disease-specific mortality of <2% (3). However, at the time of
diagnosis, pediatric patients often present with more advanced
disease, and they frequently suffer from persistent or recurrent
disease due to metastatic lymph nodes or lung metastases (3).
The prevalence of different mutations in adult thyroid cancer
has been presented in various reports. The most common genetic
alteration is BRAF (29–83%) with an overall prevalence of
*44% (4–6). The prevalence of RET/PTC rearrangements in
adults has been estimated to be*35% (7). Point mutations in
HRAS, KRAS, and NRAS are less frequent in PTC, with an
overall frequency of 10–20% (8), whereas a higher prevalence
(40–50%) has been reported in follicular carcinomas (9,10).
Finally, PAX8/PPARc rearrangements are found in 30–40% of
follicular adult thyroid carcinoma, and rarely in FVPTC (11).
The prevalence and type of mutations appear to differ
between adult and childhood thyroid carcinoma, though pe-
diatric data are still limited (1). Initial reports with relatively
small sample sizes have shown a much lower prevalence of
BRAF mutations in pediatric populations, ranging from 0% to
24% (12–14). In contrast, two recent reports demonstrated a
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much higher prevalence of the mutation in pediatric PTC of
34.5% and 71.4% (15,16). Sporadic pediatric thyroid cancer
shows a variable prevalence of RET/PTC rearrangements,
ranging from 37.5% to 71%, with RET/PTC1 being the pre-
dominant mutation (17–19). RASmutations are uncommon in
children and adolescents (20–22). The significance of these
genetic mutations in terms of tumor presentation, progression,
and response to therapeutic interventions in pediatrics is not
clear. Therefore, this study investigated the rate of the com-
mon mutations implicated in non-medullary pediatric well-
differentiated thyroid carcinoma (WDTC) in patients who
underwent surgery at the authors’ institution. This is the first
pediatric study where all four mutation classes were examined
on thyroidectomy-obtained thyroid tissue, and the findings
were recently reported as an abstract (23). Correlations be-
tween genotype and clinical phenotype were also explored.
Materials and Methods
Patients aged £18 years old who underwent thyroid surgery
and who were treated at Rady Children’s Hospital San Diego
(RCHSD) for thyroid cancer were included after Institutional
Review Board (IRB) approval was obtained. The patients
were identified based on ICD9 codes (193, 244.0, 244.1), and
review of pathology records. Patients with medullary carci-
noma were excluded. Forty-six consecutive children and
adolescent patients with WDTC were identified between
2001 and 2013. Tumors of patients with only one tissue block
available were not submitted for analysis. A total of 42
formalin-fixed, paraffin-embedded (FFPE) tissue blocks from
the thyroid gland obtained at the time of thyroid surgery were
sent to Quest Diagnostics Nichols Institute for mutational
analysis as a collaborative research study. The protocol was
IRB approved to analyze these blocks for commercially
available BRAF, NRAS, HRAS, and KRAS point mutations, as
well as RET/PTC and PAX8/PPARc rearrangements, using
validated molecular methods.
Total nucleic acid (DNA and RNA) was extracted from
thyroid FFPE specimens using an Agencourt FormaPure
FFPE extraction Kit (Beckman Coulter, Indianapolis, IN)
according to the manufacturer’s protocol (24). Molecular
testing was performed blinded to the result of cytopatholo-
gical diagnosis. BRAFV600E and BRAFK601E mutations were
detected by real-time polymerase chain reaction (PCR) using
allele-specific primers and probes using TaqMan Universal
PCR Mix (Life Technologies, Grand Island, NY). The mix-
ture was pre-amplified for 14 cycles on ABI Veriti with de-
naturation at 95C for 15 sec, annealing at 56C for 30 sec, and
extension at 72C for 30 sec. The PCR products were then
cleaned up with Ampure (Beckman Coulter) and subjected to
40 cycles of PCR amplification on ABI 7900 (Life Technol-
ogies) with denaturation at 95C for 15 sec, annealing at 62C
for 30 sec, and extension at 68C for 30 sec, and the result was
analyzed by SDS software (Life Technologies). Sanger se-
quencing was performed on the positive cases forBRAFV600E.
Six out of 10 samples verified the presence of BRAFV600E
mutation, while four of the samples failed to amplify, likely
not having enough DNA and/or having fragmented DNA
smaller than the target size for Sanger sequencing.
RAS mutations were detected by pyrosequencing targeting
codons 12, 13, and 61 of HRAS, KRAS, and NRAS. Extracted
DNA was mixed with biotinylated primers and subjected to 45
cycles of PCR amplification (denaturation at 94C for 30 sec,
annealing at 60C for 30 sec, and extension at 72C for 30 sec).
After PCR, DNA strands were separated on a PyroMark Q96
vacuum workstation (Qiagen, Valencia, CA). Then pyr-
osequencing was performed using a PyroMark Q96 MD in-
strument (Qiagen) according to the manufacturer’s protocol.
RET/PTC1, RET/PTC3, and PAX8/PPARc rearrangements
were detected by real-time reverse transcription PCR. Ex-
tracted RNA was first reverse transcribed into cDNA using
Superscript III (Life Technologies), then mixed with
sequence-specific primers and probes in TaqMan Universal
PCR Mix. The mixture was subjected to 45 cycles of PCR
amplification (95C for 15 sec, then at 60C for 60 sec) on
ABI 7900, and the result was analyzed by SDS software. For
PAX8/PPARc, the cDNA was pre-amplified as described
above before qPCR. Three cases (7%) were excluded from
the data analysis, all due to RNA quality issue in the samples.
Four cases failed to result part of the RAS mutation analysis
(HRAS and/orNRAS), but as two had mutations in other genes
(one in BRAF, the other a PAX8/PPARc rearrangement), only
the other two that had no mutations in other genes were ex-
cluded. The third case excluded failed both RET-PTC and
PAX8/PPARc analysis. In the final genotype-phenotype
analysis, patients were included with either one positive
mutation or who were genotyped for all cited molecular
markers. A total of 39 such cases met the above criteria.
A comprehensive chart review was performed, including
patients’ demographics, family history, history of external
beam or other radiation exposure, and disease characteristics
such as histology and tumor size. The staging and the type of
metastasis were based on initial surgery and the whole-body
scan findings following the initial radioiodine 131I treatment.
Statistical analysis was performed with IBM SPSS Sta-
tistics for Windows v22 (IBM Corp., Armonk, NY). Chi-
square and Fisher’s exact tests were used when appropriate to
compare the rates of the various mutations with different
clinical characteristics (e.g., presence of lymph node metas-
tasis or thyroiditis). The p-value was considered statistically
significant when it was <0.05 and as a trend with borderline
significance when it was ‡0.05 and <0.10.
Results
Patient characteristics
A total of 39/42 patients were included in the final analysis.
The number of thyroid cancer cases seen at RCHSD in-
creased significantly after 2005, with 89.7% of the cases di-
agnosed with non-medullary thyroid cancer after 2005,
which is in accordance with the SEER incidence data for
pediatric thyroid cancer (2). Demographic data are shown in
Table 1. The mean age at diagnosis was 14.7 – 2.6 years, with
females (mean= 14.9 years) being slightly older than males
(mean = 14.1 years; p = 0.235). As in other pediatric series
(13,17,25,26), there was a female predominance (74.4%).
The majority of the patients were Hispanic (56.4%) of
Mexican American descent, and Caucasian (35.9%; Table 1).
The histologic cancer types included 28 (71.8%) classic PTC,
six (15.4%) FVPTC, and five (12.8%) FTC. The distribution
is similar to the reported pediatric WDTC SEER data (25),
for rates of PTC (64.5%), FVPTC (24.7%), and FTC (12.5%).
Two of the patients with PTC had a history of radiation
exposure. One was treated with cranial radiation for an
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anaplastic ependymoma and the other with cranial and spinal
radiation for medulloblastoma. The latency period from ra-
diation treatment to diagnosis of thyroid cancer was nine and
seven years, respectively. Both patients’ molecular testing
was negative.
As detailed in Table 1, almost one third of the tumors were
2–4 cm in size, close to 30% were >4 cm, and the rest were
<2 cm. Neck dissection was performed in 21/39 (53.8%) pa-
tients; seven (33.3%) had central neck dissection, 13 (61.9%)
both central and lateral, and one dissection of compartment I
(not associated with an ectopic thyroid tissue). Neck dissec-
tions were planned if there were clinically and/or radiological
positive nodal disease preoperatively, and occasionally neck
dissections were performed based on the surgeon’s determi-
nation of pathologic nodal disease intraoperatively with
judicious use of frozen sections. Prophylactic central com-
partment (level VI) or lateral neck dissections were not rou-
tinely performed at this institution. Twenty-one of the patients
(53.8%) were found to have pathologically positive nodal
metastasis and almost all with PTC (95%). Only one patient
with FVPTC had lymph node metastasis at diagnosis, and
none of those with FTC ( p = 0.002). Radioiodine ablation was
administered to 37/39 patients. One subject did not receive
radioactive iodine (RAI) treatment after thyroidectomy due to
a small tumor (<1 cm) and one was lost to follow-up. All cases
were presumed to be RAI avid at the time of their initial
therapeutic 131I course, as this is more likely to be the case in
pediatric tumors (27). The post 131I treatment whole-body
scan revealed uptake indicative of neck lymph metastasis in
four patients, all of whom already had positive lymph nodes
identified during their initial thyroidectomy. Pulmonary me-
tastases were noted, per available post 131I data, in 2/26 pa-
tients with PTC, and in one subject with FVPTC. The findings
were confirmed by subsequent computed tomography (CT) in
the two PTC cases. The mean initial 131I dose was 130 mCi
(range 54–184.2 mCi). Four patients had more than one 131I
course due to persistent metastases. The mean follow-up pe-
riod was 34.4 months.
Thyroiditis was diagnosed in 16/39 (41%) patients based
on either pathology or positive thyroid antibodies. Most had
thyroglobulin (Tg) antibodies measured together with anti-
thyroid peroxidase (anti-TPO) antibodies before their thy-
roidectomy, and all had documented post-thyroidectomy Tg
level and antibody titers. Of the 39 patients, 28 had anti-TPO
antibody testing, and 12 (43%) were elevated. Thirteen
(81.25%) of those with thyroiditis were diagnosed with PTC,
and three (18.75%) with non-PTC ( p = 0.27). From the cases
with positive mutations, 62.5% of the PTC cases had thy-
roiditis compared with 20% of the non-PTC cases ( p= 0.01).
Patients with thyroiditis compared with those without thy-
roiditis had mutations in 68.7% versus 43.5%, respectively
( p= 0.12), and a BRAFV600E mutation was present in both
groups. The small number of cases with mutations does not
allow us to comment on whether thyroiditis affects the type of
mutation noted.
Mutational analysis
Mutations were noted in 21/39 (53.8%) samples. A detailed
breakdown of the various mutations is shown in Table 2.
Table 1. Patient Characteristics
Characteristic No. (%)
Age at diagnosis (years)
Mean (SD), range 14.7 (2.6), 7.9–18.4
Sex
Male/female 10 (25.6)/29 (74.4)
Ethnicity
Caucasian 14 (35.9)
Hispanic 22 (56.4)
African American 1 (2.6)
South Asian 2 (5.1)
Histologic subtype
PTC 28 (71.8)
FVPTC 6 (15.4)
FTC 5 (12.8)
Tumor size (cm)
<2 15 (38.5)
2–4 12 (30.8)
>4 12 (30.8)
Neck dissection
Central 7 (17.9)
Central and lateral 13 (33.3)
Other 1 (2.6)
No neck dissection 18 (46.2)
Lymph node metastasesa 21 (53.8)
Pulmonary metastasesb 3 (8.1)
Thyroiditis 16 (41)
aLymph node metastasis at the completion of initial treatment.
bPulmonary metastases noted post initial radioiodine 131I course.
PTC, papillary thyroid carcinoma; FVPTC, follicular variant of
PTC; FTC, follicular thyroid carcinoma.
Table 2. Distribution of Genetic Mutations/Alterations
Mutation BRAFV600E
RET/PTC
RAS
PAX8/PPARc1 3
H codons
12/13 H codon 61
K codons
12/13/61
N codons
12/13 N codon 61
Sample 39 39 39 39 37 39 38 38 37
n 9 5 1 0 0 0 0 2 4
M/F 3/6 1/4 0/1 0/2 1/3
PTC 9 5 1 1
FVPTC 0 0 0 0 3
FTC 0 0 0 1 1
n total (%) 9 (23.1) 6 (15.4) 2 (5.3) 4 (10.8)
M, male; F, female.
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Multiple mutations were not identified in any patient. The
most prevalent mutation was BRAFV600E, found exclusively
in PTC (Fig. 1). No BRAFK601E was noted. A total of six RET/
PTC rearrangements were identified, and only in PTC. Three
out of six FVPTC were positive for PAX8/PPARc, which was
also found in one FTC. Two NRAS codon 61 mutations
(c.181C>A, p.Q61K) were also found, one in FTC and one in
PTC.
Of the 28 patients with classic PTC, 57.1% (n = 16) had
mutations. Mutations were noted in 50% (n = 3/6) of those
with FVPTC and in 40% (n= 2/5) of those with FTC, but the
numbers in those two cancer types were small. BRAFV600E
was the most common mutation in PTC (Fig. 2). It was found
in 32.1% of PTC cases, and 77.8% and 22.2% of those cases
were Hispanic and Caucasian, respectively ( p = 0.10). RET/
PTC was found in 21.4% of PTC cases and was evenly dis-
tributed, with 33.3% being Hispanic and 33.3% Caucasian.
The five patients with a RET/PTC1 rearrangement tended to
have smaller tumors, four being <2 cm, and only one >4 cm,
but 80% of them had positive lymph nodes.
Approximately 89% of the BRAFV600E mutations were
found in adolescents >15 years of age, and 11.1% in £15
years old (Fig. 3), while RET/PTC rearrangements were ex-
clusively found in children <15 years old ( p = 0.003). Taking
into consideration the female predominance in WDTC, no
sex differences were noted in the relative rate of BRAFV600E
mutations and RET/PTC rearrangements ( p = 0.6).
There was no statistically significant difference noted in
the tumor size, lymph node status, and iodine-avid distant
metastasis at the completion of the initial treatment (thy-
roidectomy and 131I ablation), based on the presence or the
type of mutations. Of all the patients found to be positive for a
mutation, 66.7% underwent a neck dissection in comparison
with 38.9% of those who did not have a mutation ( p = 0.113).
Alternatively, those who presented with positive lymph
nodes at diagnosis were not more likely to have positive
mutations detected. Of the PTC cases positive for a mutation,
81.25% presented with lymph node metastasis at diagnosis
versus 58.3% of those without a mutation ( p = 0.231). Close
to 89% (88.9%) of the cases with a BRAFV600E mutation and
83.3% of the cases with a RET/PTC rearrangement had
central and/or lateral neck dissection, all with positive lymph
nodes. Of the BRAFV600E-positive PTC tumors, 22.2% were
>4 cm, and of the cases with a RET/PTC rearrangement, 33%
were >4 cm ( p = 0.393). There were no iodine-avid distant
metastases noted in the PTC cases positive for a mutation,
whereas two cases, representing 18.2% of the PTC cases
without a mutation, had distant pulmonary metastasis iden-
tified at diagnosis. The FVPTC case with pulmonary metas-
tasis was positive for a PAX8/PPARc rearrangement.
Discussion
The presence of the common mutations and rearrangements
reported for adults with WDTC has been described previously
in non-medullary pediatric thyroid carcinoma (12–19). How-
ever, prior pediatric studies tended to be small, and typically
examined only one type of mutation, with recent studies fo-
cusing on BRAFV600E (15,16). The current study is the first
pediatric study to examine all four mutation types simulta-
neously on thyroidectomy-obtained thyroid tissue from his-
tologically confirmed WDTC using a commercially available
analysis, performed by Quest Diagnostics (23). The recently
published pediatric guidelines (28) state that molecular studies
on fine-needle aspiration (FNA) cannot be recommended in
routine clinical practice, as they are not yet validated. Data
from this study may help fill some of the knowledge gaps. The
currently reported study population is mostly of Hispanic
(Mexican American) and Caucasian descent (both groups re-
presenting 92.3% of all cases). Due to the lack of long-term
follow-up and very small number of recurrences (data not
shown), only genotype–phenotype correlations are reported
on, with the clinical presentation and course up to six months
post-diagnosis. Buryk et al. recently published their experi-
ence with mutational analysis of these four genes on FNA
material from thyroid nodules from 89 pediatric patients up to
the age of 18 years, of whom 24 had thyroid cancer, and only
12 had PTC (29). However, all nodules with mutations were
found to be malignant, similar to their earlier conclusions in a
pediatric study on patients up to 21 years of age, with molec-
ular data available on 66 FNAs (30).
FIG. 1. Mutational analysis by histology.
FIG. 2. Mutational analysis in PTC.
FIG. 3. Mutational distribution by age in PTC.
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It was noted that 56.4% of the present pediatric cohort was
Hispanic, and 35.9% was Caucasian. This is similar to their
relative distribution in the general pediatric population in San
Diego County (<18 years old), which is 45.4% versus 34.1%,
respectively (31). This is in contrast to SEER data, where the
incidence of WDTC was greater in white compared with
Hispanic children (2) and may be due to the more varied
origins of Hispanic patients nationally, whereas in this San
Diego cohort they were all Mexican American. BRAFV600E
was the most common mutation in all cases and was ex-
clusively found in PTC cases. It was noted mainly in older
adolescents of Hispanic descent, a finding that was not rec-
ognized previously, and will require corroboration in future
studies that also involve Hispanic subjects. RET/PTC re-
arrangements in PTC were exclusively found in younger
patients (£15 years old), with a lower prevalence than prior
U.S. pediatric studies. It is unclear if puberty has an impact on
the type of mutation or whether it is just the age itself. The
present finding of a cutoff at 15 years of age affecting the
likelihood of being positive for a mutation (Fig. 3), while
arbitrary, should be further explored. At the completion of the
initial treatment, there was no statistically significant differ-
ence between tumor size and lymph node metastases based
on the presence or type of the mutation; the number of distant
metastasis is too small to draw any conclusions. Distant
metastases were primarily identified with post-therapeutic
131I whole-body scans. Other imaging such as CT was not
done in all of the patients. The majority of children with
pulmonary metastases have micronodular disease that typi-
cally demonstrates excellent RAI uptake. Because of this,
distant metastases in children are more amenable and re-
sponsive to 131I therapy compared with adults. In the present
cohort, Tg levels were measured in each patient post treat-
ment, and there was no suspicion for metastases based on
those levels.
BRAFV600E is considered to be the most common mutation
in adult thyroid carcinoma (4–6,32) and was initially thought
to have a much lower prevalence in the pediatric population.
In a series of 15 cases of children exposed to radiation
(Chernobyl), no BRAFV600E mutations were found in those
<15 years of age, whereas 8/33 (24%) cases in the older age
group (15–31 years old) harbored this mutation (12); this
latter rate does not truly reflect pediatric patients only. In two
pediatric series of sporadic PTC published a decade ago, the
BRAFV600E mutation prevalence was 0% (13) and 20% (14),
respectively. In two more recent reports from the United
States, the rates were higher (15,16), perhaps signifying a
shift. In the first study, the BRAFV600E mutation was detected
in 63% of pediatric PTC and FVPTC cases (n = 27) and
71.4% of classic PTC cases (n = 21) (15). The mean age of the
cohort was 18.6 years (range 5.8–21.2 years). The authors did
not find any significant correlation between BRAFV600E status
and age, though most of their BRAFV600E-positive cases
(70.6%) were found in children >15 years of age, similar to
the finding reported here. Previous reports speculated that
higher rates of BRAF mutations likely reflect an older age
distribution (33). Another recent study found BRAFV600E
mutations in 36.8% (n = 19) of their overall cohort and in
63.6% (n = 11) of PTC cases (16). The reported median age
was 13.6 years (range 2.8–18 years). Of the BRAFV600E-
positive cases, 4/7 were found in children >15 years of age.
This study had a larger cohort of 39 cases, with 28 of those
being classic PTC. A higher prevalence of BRAFV600E mu-
tation was also found compared with the older pediatric re-
ports (13,14). The present study reports 23% of all cases and
32.1% of the PTC cases being positive for BRAFV600E. The
method used for the detection of theBRAFV600E mutation was
allele-specific real-time PCR, which is considered to be more
sensitive than Sanger sequencing. In order to verify the re-
sults, the mutations were confirmed by Sanger sequencing in
6/10 of the BRAFV600E-positive samples. Four of the samples
failed to amplify due to technical reasons. In agreement with
two recent reports (15,16), the majority of the BRAFV600E-
positive cases were found in children >15 years of age. The
finding is important, as it has been speculated in the past that
the presence of a BRAFV600E mutation might contribute to the
different biological behavior of adult versus pediatric PTC.
The relationship between this mutation and the clinicopath-
ological outcomes of PTC in adults have been investigated in
several studies (4,34–37). There is no consensus regarding
the correlation of the disease characteristics and the presence
of a BRAF mutation. In the majority of the studies, significant
associations have been found between the presence of a
BRAF mutation and extrathyroidal invasion, advanced
stages, distant metastasis, thyroid recurrence, and loss of RAI
avidity in the recurrent thyroid cancer. However, a recent
large study of adults with PTC failed to demonstrate the same
correlations (37). This might be explained by recent findings
from the Cancer Genome Atlas Research Network, which
suggest that BRAFV600E-positive PTC should not be consid-
ered a homogeneous group in clinical studies (38).
Fewer studies have addressed the same issue in pediatric
thyroid carcinoma, but in none of those was presence of the
BRAFV600E mutation associated with more aggressive disease
(13,39), or correlated with the extent of the disease at diag-
nosis or risk factors associated with poor prognosis (15,16).
The present study confirms that latter observation, but like the
other small pediatric studies, it is not powered to detect a
significant association between the presence of BRAFV600E
and tumor behavior.
Although the prevalence of RET/PTC rearrangements in
thyroid tumor varies in different series, it has been reported to
be more frequent in childhood than in adulthood thyroid
cancer (18,40). Of the 13 different types of RET/PTC re-
arrangements described, RET/PTC1 and RET/PTC3 are the
most common. RET/PTC1 and in particular RET/PTC3 have
been highly associated with radiation-induced PTC (18).
None of the RET/PTC cases in the current report had a history
of radiation-induced PTC. RET/PTC rearrangements in this
cohort were found in 21.4% of the PTC cases, which repre-
sents a much lower prevalence than that found in prior pe-
diatric studies, such as a report of an overall frequency of
45.5% in a cohort of 33 American children with sporadic PTC
(17). In a recent small pediatric series on FNA material, 3/12
PTC cases had RET/PTC rearrangements (25%) (29). In a
report from Italy, 40% of children with PTC, unexposed to
radiation, were positive for RET/PTC rearrangements (19).
All of the current RET/PTC positive cases were children £15
years of age. When Elisei et al. compared the frequency of
RET/PTC rearrangements in children and adults within the
same country, they did not find any significant difference, and
they concluded that age does not predict the presence of RET/
PTC rearrangements in PTC, but rather that it is a matter
of different ethnic groups (40). The cohort presented here
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consists predominantly of children of Hispanic descent or
Caucasians (Table 1). Both RET/PTC and BRAFV600E were
found only in classic PTC (n = 28). A novel finding from this
cohort was the high rate of BRAFV600E mutations in those of
Hispanic descent (77.8% of cases). This contrast with RET/
PTC rearrangements, which were evenly distributed.
The PAX8/PPARc rearrangement is found in 30–40% of
adult FTC, and rarely in FVPTC (11), whereas 3/6 FVPTC
cases in the present study were positive for PAX8/PPARc,
and 1/5 cases with FTC was positive for a PAX8/PPARc
rearrangement. A larger series is needed to explore whether
these findings are consistent in pediatric WDTC.
In the current study, a NRAS Q61 mutation was found in
two (5.1%) cases (one FTC, one PTC). The low mutation
frequency for RAS mutations in pediatric PTC (3.6%) is
similar to those reported previously (22–24), and the signif-
icance of the mutation frequency for RAS mutations in pe-
diatric FTC (20%) needs to be further investigated due to the
small sample size in this category of patients.
Thyroiditis was documented in 41% cases, a higher rate
than in the general population, where 4.8% of adolescents
(12–19 years old) in the United States are reported to have
positive anti-TPO antibodies (41). In addition, the finding of
thyroiditis being more prevalent in PTC (81.5%) versus non-
PTC (18.7%) cases ( p = 0.27) may reach significance in a
larger cohort. There are mixed data reported on the associa-
tion of autoimmune thyroiditis and differentiated thyroid
cancer. Most studies based on FNA biopsy report no corre-
lation, whereas the studies on thyroidectomy tissue report a
positive relationship. In patients with Hashimoto’s thyroid-
itis, the average rate of PTC is 1.20% in studies using FNA
and 27.56% using tissue from thyroidectomies (42). A recent
study based on analysis of thyroidectomy tissue failed to
demonstrate an association between anti-TPO antibodies and
the diagnosis of thyroid cancer (43). In a study from Italy, 39/
365 children with autoimmune thyroiditis had FNA per-
formed for suspicious thyroid nodules, and 11 were found
to have a PTC on histology, giving an overall prevalence
of 3% (44).
One of the limitations of the study is that it is retrospective.
Obtaining consecutive cases helps eliminate some bias. The
single-center sample size is small, although larger than pre-
vious studies in pediatrics. The mean follow-up period was
2.9 years. Since WDTC is typically a slowly progressive
tumor, a longer follow-up is needed for better genotype–
phenotype analysis of recurrence. Extracted DNA and RNA
from FFPE tissues are known to be fragmented and prone to
degradation over time (45). The samples that failed to result
were from patients diagnosed between 2001 and 2008 and not
necessarily from the oldest samples. Overall, genotyping of
RET/PTC and RAS was associated with some technical dif-
ficulties in a minority of patients, which did not seem to affect
the overall conclusions.
In conclusion, this study demonstrates that in a pediatric
population of WDTC consisting mostly of Hispanic and
Caucasian patients, the frequency of the BRAFV600E mutation
is comparable to that found in the adult population, and it is
mostly observed in those >15 years old and of Hispanic de-
scent. RET/PTC rearrangements were less prevalent in this
cohort compared with prior pediatric studies. More advanced
molecular analysis using next-generation sequencing will
likely reveal other types of mutations, rearrangements, and
fusions that may affect the genotype–phenotype correlations.
A larger, multicenter, and ethnically diverse pediatric cohort
followed long term is needed to study genotype–phenotype
correlations better in thyroid cancer at diagnosis and beyond.
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